Email this article Irreversible electroporation of locally advanced unresectable pancreatic cancer
- Authors: Patyutko Y.I1, Polyakov AN1, Kudashkin NE1, Podluzhnyi DV1, Chistyakova OV1
-
Affiliations:
- N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation
- Issue: Vol 19, No 3 (2017)
- Pages: 58-63
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/27156
- ID: 27156
Cite item
Full Text
Abstract
Aim: to improve the results of treatment of patients with locally advancesd pancreatic cancer. Matherials and methods. From February 2015 till June 2017 there was performed 6 irreversible electroporations of unresectable pancreatic cancers, one of which was combined with palliative gastropanreatoduodenectomy. The median tumor size was 41.7 mm (range from 22 to 65 mm). The median quantity of treated areas was 2.3 (1-5). Perioperative treatment was routinely used. Results. Two patients had complications. One died on the 21st day from the pancreonecrosis with parapancreatic abscesses. Autopsy showed there was no evidence of tumor cells in the site of electroporation performed. In the other case there were revealed several foci of destruction around the area of electroporation which required sanation under the endoscopic US-guidance. In different periods of observation (1-, 3-, 4 and 12 month) four patients were alive without sign of progression. One patient died in 13 month from progression. Conclusion: irreversible electroporation - is one of the effective local treatment methods for the patiemts with unresectable nonmetastatic pancreatic cancer. To increase treatment results it is recommended to combine electroporation with chemoor radiotherapy.
Full Text
##article.viewOnOriginalSite##About the authors
Yu I Patyutko
N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation
Email: mikpat@mail.ru
д-р мед. наук, проф., вед. науч. сотр. хирургического отд-ния №7 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
A N Polyakov
N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation
Email: dr.alexp@gmail.com
канд. мед. наук, науч. сотр. хирургического отд-ния №7 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
N E Kudashkin
N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
D V Podluzhnyi
N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
O V Chistyakova
N.N.Blokhin National Medical Reseach Center of Oncology of the Ministry of Health of the Russian Federation115478, Russian Federation, Moscow, Kashirskoe sh., d. 23
References
- Злокачественные заболевания в России в 2012 году (заболеваемость и смертность). Под ред. А.Д.Каприна, В.В.Старинского, Г.В.Петровой. М.: МНИОИ им. ПАГерцена, 2014.
- Онкология. Клинические рекомендации Под ред. МИДавыдова. М.: РОНЦ, 2015.
- Suker M, Beumer B.R, Sadot E. et al. FOLF1R1NOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol 2016; 17 (6): 801-10.
- Von Hoff D.D, Ervin T, Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl Med 2013; 369:1691-703.
- Покатаев И.А, Тюляндин С.А Системная лекарственная терапия метастатического рака поджелудочной железы. Современная Онкология. 2016; 18 (1): 20-4.
- Loehrer P.J, Feng Y, Cardenes H et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29:4105-12.
- Chauffert B, Mornex F, Bonnetain F al. Phase 111 trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01FFCD/SFRO study Ann Oncol 2008; 19: 1592-9.
- Ткачев С.И.,Медведев С.В., Знаткова Я.Р. и др. Возможности стереотаксической лучевой терапии при паллиативном лечении больных раком поджелудочной железы. Вопр. онкологии. 2015; 61 (1): 121 -4.
- Balaban E.P, Yee N.S, Mangu P.B. et al. American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol 2016; 34 (22): 265468.
- Goyal K, Einstein D, Jbarra R.A et al. Stereotactic body radiation therapy for nonresectable tumors of the pancreas. Surg Res 2012; 174 (2): 319-25.
- Zeng X.L, Wang H.H, Meng M.B. Stereotactic body radiation therapy for patients with recurrent pancreatic adenocarcinoma at the abdominal lymph nodes or postoperative stump including pancreatic stump and other stump. Onco Targets Ther 2016; 9:3985-92.
- Edd J.F., Horowitz L, Davalos R.V et al. In vivo results of a new focal tissue ablation technique: irreversible electroporation. IEEE Trans Boomed Eng 2006; 53:1409-15.
- Narayanan G, Hosein P.J, Arora G. et al. Percutaneous Irreversible Electroporation for Downstaging and Control of Unresectable Pancreatic Adenocarcinoma. J Vasc Interv Radiol 2012; 23:1613-21.
- Martin R.C., Kwon D, Chalikonda S. et al. Treatment of200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation Safety and Efficacy Ann Surg 2015; 262:486-94.
- Philips P, Hays D, Martin R.C. Irreversible electroporation ablation (IRE) of unresectable soft tissue tumors: learning curve evaluation in the first 150 patients treated. PLoS One 2013; 8: e76260. doi: 10.1371/journal.pone.0076260
